US2010291138A1PendingUtilityA1
Vaccine
Est. expiryMar 19, 2019(expired)· nominal 20-yr term from priority
Inventors:Carine CapiauMarguerite DeschampsPierre DesmonsCraig Antonyjoseph LaferriereJan PoolmanJean-Paul Prieels
A61P 37/04A61P 31/00A61P 27/06A61P 27/16A61P 31/04A61P 11/00A61K 47/646A61K 39/092A61K 2039/6037A61K 39/102Y10S424/831A61K 39/12A61K 2039/55505A61K 39/095A61K 2039/6068A61K 2039/55572A61K 2039/70A61K 2039/6075A61K 39/155A61K 39/385Y02A50/30
46
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen form Streptococcus pneumoniae , and optionally a Th1-inducing adjuvant.
Claims
exact text as granted — not AI-modified1 . An immunogenic composition comprising Streptococcus pneumoniae polysaccharide serotype 18C conjugated to protein D from Haemophilus influenzae , and 3-0 deacylated monophosphoryl lipid A (3D-MPL), wherein the immunogenic composition is substantially devoid of aluminum-based adjuvant.
2 . The immunogenic composition of claim 1 further comprising pneumolysin from Streptococcus pneumoniae.
3 . The immunogenic composition of claim 2 , wherein the pneumolysin is detoxified by chemical treatment or mutation.
4 . A vaccine comprising the immunogenic composition of claim 1 .
5 . A vaccine comprising the immunogenic composition of claim 2 .
6 . An immunogenic composition comprising Streptococcus pneumoniae polysaccharide serotype 18C conjugated to protein D from Haemophilus influenzae , pneumolysin from Streptococcus pneumoniae , and 3-0 deacylated monophosphoryl lipid A (3D-MPL), wherein the immunogenic composition is devoid of aluminum-based adjuvant.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.